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Tyrosine hydroxylase (TH) deficiency is a rare autosomal recessive neurometabolic disorder with variable phenotypes. It is almost 
exclusively caused by missense mutations in the 
TH gene and its promoter region on chromosome 
11p15.5. In 1971, Castaigne et al. was the first to report 
this condition in two brothers.1 Since then, it has been 
reported in 50 patients from 41 families worldwide.2 
The only reported cases of TH deficiency in 
the Arab world were from Lebanon; the onset of 
hypokinaesia, rigidity and dystonia was observed in 
patients under 12 months old. In these cases, all the 
patients showed a good clinical response to therapy 
with levodopa (L-dopa).3,4 This case is the first instance 
of TH deficiency among the Middle Eastern population 
in an infant carrying a novel mutation in the TH gene. 
The patient subsequently demonstrated an excellent 
response to treatment with L-dopa. Informed consent 
was obtained from the patient’s parents for all tests 
and written consent was obtained for the publication 
of this case report.
Case Report
A 10-month-old boy was referred to the Department of 
Clinical Neurosciences at Salmaniya Medical Complex 
in Manama, Bahrain, with a three-month history of 
global developmental delay and excessive sleepiness. 
The mother’s pregnancy had been uneventful. He was 
born at term with a birth weight of 3.4 kg (within the 
25th percentile), a head circumference of 34 cm (within 
the 10th percentile) and a length of 50 cm (within the 
25th percentile). His Apgar scores were 8 and 9 at one 
and five min, respectively. The postnatal period was 
uneventful. The patient was the first child of healthy 
consanguineous parents. There was no family history 
of neurological disorders. 
A visual examination of the patient showed an 
alert infant who was able to fix, follow and smile 
responsively. He showed reduced facial expression 
but no ptosis. Full extra-ocular movements, normal 
saccades and no signs of nystagmus were observed. His 
optic fundi were normal. The patient had occasional 
episodes of uprolling of the eyes with head extension. 
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abstract: Tyrosine hydroxylase (TH) deficiency is a rare autosomal recessive and often treatable neurometabolic 
disorder with variable phenotypes. More than 20 pathological mutations have been identified in patients with TH 
deficiency. We report the case of a 10-month-old male patient who presented with developmental delay, hypotonia 
and oculogyric crises to the Salmaniya Medical Complex in Manama, Bahrain. At a later stage, he developed 
orofacial dyskinaesia and tremors with hyper-reflexia and clonus. A magnetic resonance imaging scan of the 
brain showed mild atrophy with widened ventricles and genetic testing revealed a novel homozygous mutation 
(c.938G>T; p.Arg313Leu) in exon 9 of the TH gene. The patient showed a remarkable response to treatment using 
combined levodopa-carbidopa. In this case, the orofacial dyskinaesia may be a specific clinical association unique 
to this novel mutation, which is the first to be described in Bahrain and the Middle East.
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نادر، غالبا" ما ميكن عالجه، وله ظواهر �رسيرية متغرية ومتعددة مت  ا�ستقالبي ع�سبي وراثي  اعتالل  التايرو�سني هايدروك�سيليز هو  نق�س  امللخ�ص: 
اكت�ساف اأكرث من 20 طفرة وراثية مر�سية منوطة بهذه احلالت. يف هذا التقرير نناق�س حالة مري�س قدم اإلينا يف �سن الع�رسة �سهور باأعرا�س �سملت تاأخر 
يف النمو، رخاوة يف توتر الع�سالت مع اأزمات �سخو�س الب�رس. بعد ذلك، ظهرت عليه اأعرا�س احلركات الالإرادية يف الفم والوجه مع اهتزازات و فرط يف 
املنعك�سات الع�سبية. اأظهر ت�سوير الرنني املغناطي�سي للدماغ �سمور خفيف مع ات�ساع يف البطينني، و ك�سفت الختبارات اجلينية عن وجود طفرة جينية 
ا�ستجابة ملحوظة  ا�ستجاب املري�س  التايرو�سني هايدروك�سايليز.  اأك�سون ٩ على جني  )c.938G>T;p.Arg313Leu( يف  جديدة مع تغري متماثل 
للعالج املركب بعقاري ال ل-دوبا/ الكاربي دوبا. يف هذه احلالة ،حدث عر�س اخللل احلركي الفموي الوجهي والذي قد يكون موؤ�رسا فريدا من نوعه لهذا 
التحوراجليني اجلديد، و تعترب هذه احلالة الأوىل من نوعها يف البحرين وال�رسق الأو�سط.
مفتاح الكلمات: التايرو�سني هايدروك�سايليز؛ اخللل التوتري امل�ستجيب للدوبا؛ تقرير حالة؛ البحرين.
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This occurred without a change in his sensorium, 
which is consistent with oculogyric crises. He was able 
to lift his head to 45 degrees while lying in a prone 
position. He had increased muscle tone in his four 
limbs, generally with brisk, deep tendon reflexes. The 
remainder of the examination was unremarkable.
Laboratory investigations showed normal serum 
amino acids, tandem mass spectrometry, urine 
organic acids, lysosomal enzymes and very long chain 
fatty acids. Renal, bone and liver function tests were 
also performed. Computed tomography (CT) and 
magnetic resonance imaging (MRI) scans showed 
signs of mild brain atrophy. An electroencephalogram 
(EEG) revealed intermittent bursts of sharp waves over 
the frontal regions.
In spite of ongoing rehabilitation therapy, the 
patient continued to regress; he became more 
hypotonic and developed tremors with clonus in both 
ankles. His speech and cognition progressed slowly. 
A physical examination at one-and-a-half years of 
age revealed prominent orofacial dyskinaesia with 
drooling and, accordingly, he was started on a trial of 
combined L-dopa-carbidopa.
After three months of treatment, the muscle tone 
in his limbs improved and he began to walk with 
support. He also began to put words together to form 
short sentences. By the age of two, he was walking 
independently. 
Dopa-responsive dystonia (DRD) was suspected 
clinically and this was subsequently confirmed 
by genetic analysis. Genomic deoxyribonucleic 
acid (DNA) from the patient and the mother was 
amplified for the gene encoding TH (National 
Center for Biotechnology Information reference 
sequence NM_199292.2) by means of a polymerase 
chain reaction (PCR). A PCR was performed using 
the AmpliTaq Gold® 360 Master Mix (Applied 
Biosystems®, Thermo Fisher Scientific Inc., Carlsbad, 
California, USA) as described by the manufacturer. 
Forward and reverse primers are available in Table 
1. The fragments that were obtained, including the 
individual exons, the splice donor site, and the splice 
acceptor site, were subjected to double-stranded 
DNA sequencing analysis on a 3730xl DNA Analyzer 
(Applied Biosystems®). The sequence analysis was 
performed using Sequencher DNA Sequencing 
Software,Version 4.8 (Gene Codes Corp., Ann Arbor, 
Michigan, USA) and SeqPilot Version 3.2.1.0 (JSI 
Medical Systems GmbH, Kippenheim, Germany) 
software. The sequence analysis primers are recorded 
in Table 2. 
The sequence analysis identified a homozygous 
mutation, c.938G>T (p.Arg313Leu), in exon 9 of the 
TH gene in the proband; the patient’s mother was 
heterozygous [Figures 1 A, B & C]. This change was 
predicted to be possibly pathogenic by the mutation 
prediction software, the Sorting Intolerant from 
Tolerant (SIFT) Tool Version 1.03 (J. Craig Venter 
Institute, Rockville, Maryland, USA). A substitution at 
position 313 from R to L was predicted to affect the 
protein function with a score of 0.01. The polyphen-2 
mutation prediction software PolyPhen-2 showed 
that this amino acid change is probably damaging, 
giving a score of 0.987 (sensitivity 0.73, specificity 
Table 1: Forward and reverse primers for amplifying the coding exons of the tyrosine hydroxylase gene
Exon Forward primer (5'→3') Reverse primer (5'→3')
1 tgtaaaacgacggccagtTGGGGAGTGAAGGCAATTAG caggaaacagctatgaccCCAACAGGGACTCAAACACC







9 + 10 tgtaaaacgacggccagtGCTACCGGGAAGACAATATCC caggaaacagctatgaccAGCAGGCAGCACACTTCAC
11 + 12 tgtaaaacgacggccagtCTTCTCCCAAACAGAGCCTGA caggaaacagctatgaccCCTGGAGGGGCTGCTGACA 
13 tgtaaaacgacggccagtCTTGTCTCTGCCCAGTCCTC caggaaacagctatgaccCTCAAGGCCAGAAGGAAGG
14 tgtaaaacgacggccagtACCAGTTGGCTCAGAAAAGC caggaaacagctatgaccAGGACAGGACCTCACCACAG
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0.96). The testing score of the Align-GVGD program 
(International Agency for Research on Cancer, 
Lyon, France) was C35; this score lies midway in 
the spectrum of output prediction classes (C0, C15, 
C25, C35, C45, C55, C65), with C65 being the most 
likely to interfere with function and C0 being the 
least likely. This mutation has not been reported in 
the Single Nucleotide Polymorphism Database, the 
Exome Variant Server or the Human Gene Mutation 
Database. At a later stage, the father was also screened 
and found to be a carrier of this novel mutation. 
Discussion
DRD is largely caused by autosomal dominant 
mutations in the GTP cyclohydrolase1 (GCH1) gene 
and, more rarely, by autosomal recessive mutations 
in the TH or sepiapterin reductase (SPR) genes.5 
It was considered unlikely that the current patient 
had DRD caused by mutations in the GCH1 gene, 
as DRD is an autosomal dominant disorder that 
presents in childhood at around six years of age.6–8 
The current patient presented in infancy with delayed 
development and hypotonia that later became more 
pronounced. He developed fine tremors with orofacial 
dyskinaesia in the second year of life which alerted the 
treating physicians to the more common diagnosis of 
TH deficiency.
TH-deficient DRD may present as pure dystonia 
or as a dystonia-plus syndrome, featuring oculogyric 
crises, mental retardation, Parkinsonism and other 
clinical features.9 TH deficiency has been divided into 
two phenotypes. The first is a progressive, hypokinetic-
rigid syndrome with dystonia and an infantile onset, 
known as type A, and the second is a complex 
encephalopathy with a neonatal/early infancy onset, 
known as type B.2 Generally, there is an overlap of 
clinical features between the two types and a variable 
response to treatment with L-dopa.10 
The patient’s presentation, clinical course and 
response to combined L-dopa-carbidopa was in 
keeping with a diagnosis of TH-deficient DRD type 
A.2 Hypokinaesia, bradykinaesia and rigidity have 
typically dominated the neurological presentation 
in reported cases with dystonia often being less 
prominent,2 as was the case for the current patient. 
However, other features, including ataxia, chorea, 
ptosis and symptoms of dysautonomia, were absent. 
The cognitive function of patients is reported to be 
improved in those who develop symptoms after their 
first year of life.2 In addition, tremors and oculogyric 
crises are reported to be mild and rare.11–13 Oculogyric 
crises are present in cases of TH-deficient DRD type 
B and in the other DRD-plus syndromes caused by 
mutations in the SPR gene.5 Excessive sleepiness has 
been described in patients with TH-deficient DRD 
types A and B as well as in individuals with SPR gene 
mutations.2,14 Dyskinaesia, on the other hand, has been 
reported mainly in TH-deficient DRD type B cases 
and is usually severe and unresponsive to treatment.2 
There has been no mention in the literature of orofacial 
dyskinaesia in patients with TH-deficient DRD type 
A. Dyskinaesias are generally reported as L-dopa-
induced side-effects when the dosage is increased 
rapidly or the drug is prescribed for long periods. 
Therefore, the presence of orofacial dyskinaesia in 
this case, prior to the patient’s L-dopa treatment, may 
represent a mutation-specific phenotype that has not 
been described previously. 
The differential diagnosis for psychomotor 
regression and dystonia includes early onset primary 
dystonia, early onset Parkinsonism and various other 
genetic and acquired disorders. 
The patient did not undergo a lumbar puncture 
to assess the major metabolites of dopamine or 
homovanillic acid (HVA). In addition, tests for the 
urine pterins concentration and the dihydropteridine 
reductase activity in the blood were not performed. 
While these investigations help support the diagnosis 
of TH deficiency, they are not diagnostic.
Although the current patient had a mild form of TH 
deficiency, brain imaging revealed mild brain atrophy 
 
Figure 1 Panel A, B & C: Sequence profiles showing the 
c.938G>T mutation in exon 9 of the tyrosine hydroxylase 
(TH) gene. Panel A shows the normal genomic sequence, 
while panels B and C show the electropherograms 
corresponding to the genomic sequence of the proband 
and his mother, respectively. The vertical arrows point 
to the normal guanine nucleotide (A) and the variant 
thiamine nucleotide which was homozygous for the 
proband (B) and heterozygous for the mother (C).
A New Tyrosine Hydroxylase Genotype with Orofacial Dyskinaesia
e400 | SQU Medical Journal, August 2014, Volume 14, Issue 3
with prominent cerebrospinal fluid spaces throughout 
the ventricular system. Similarly, a previous case 
report observed cerebral and cerebellar atrophy in an 
individual severely affected by TH deficiency.15
More than 20 pathological mutations (including a 
point mutation in the TH gene promoter region) have 
been reported in patients with TH deficiency. All of 
these individuals have been homozygous or compound 
heterozygous for TH gene mutations. Most mutations 
have been single nucleotide substitutions, the most 
common of which are c.698G>A (p.Arg233His) and 
c.707T>C (p.Leu236Pro).3,4,12,15–20 Single nucleotide 
deletions, resulting in frameshift mutations and 
protein truncation, have also been reported.18–20 
Mutations in the highly conserved cyclic adenosine 
monophosphate (cAMP) response element, within 
the TH gene promoter region, have been found in six 
families with TH deficiency.3,15
Both parents of the patient in this case report 
were found to be carriers of this mutation. They were 
subsequently offered genetic counselling to explain the 
ramifications of this genetic disorder.
Conclusion
Orofacial dyskinaesia is an uncommon presentation, 
especially for the hypokinetic-rigid syndrome of TH 
deficiency. It may be specific to the novel homozygous 
mutation (c.938G>T; p.Arg313Leu) in exon 9 of the 
TH gene; this mutation is potentially unique to the 
Middle Eastern population. 
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